Celularity (CELU) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for December 19, 2025, at 9:00 a.m. Eastern Time in Florham Park, NJ.
Shareholders can vote electronically or in person at the meeting.
Proxy materials, including the annual report and proxy statement, are available online for review.
Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2028 annual meeting.
Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.
Amendment to the 2021 Equity Incentive Plan to increase available shares by 3,500,000.
Other business may be transacted as properly brought before the meeting.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Nominees for Class I directors are Peter Diamandis, M.D., Diane Parks, and Geoffrey Ling, M.D.
Directors to serve until 2028 or until successors are elected and qualified.
Latest events from Celularity
- Q2 revenue up 312% but severe liquidity and going concern risks persist.CELU
Q2 20243 Feb 2026 - Up to 14.1M shares offered for resale; proceeds possible from warrant exercises, not share sales.CELU
Registration Filing31 Dec 2025 - Resale of up to 15.9M shares targets capital via warrants, amid ongoing losses and high risk.CELU
Registration Filing19 Dec 2025 - Annual meeting to elect director, ratify auditor, and review governance, compensation, and related-party matters.CELU
Proxy Filing2 Dec 2025 - IPO seeks $8.7M for debt and working capital amid liquidity crisis and high dilution.CELU
Registration Filing29 Nov 2025 - Strong revenue growth but high losses and liquidity risks; IPO targets $13.3M for working capital.CELU
Registration Filing29 Nov 2025 - Significant revenue decline, deepening losses, and urgent need for new capital threaten viability.CELU
Q3 202514 Nov 2025 - Annual meeting to vote on director elections, auditor ratification, and equity plan amendment.CELU
Proxy Filing7 Nov 2025 - Q2 2025 revenue fell 53% YoY, net loss widened, and going concern risks persist.CELU
Q2 202529 Aug 2025